Asthma maybe cured in the next five years after drug breakthrough, reveals a new study by Cardiff University researchers.
Researchers working in collaboration with scientists at King's College London and the Mayo Clinic (USA), described the previously unproven role of the calcium sensing receptor (CaSR) in causing asthma, a disease which affects 300 million people worldwide.
Study Sheds New Light on Asthma and Chronic Obstructive Pulmonary Disease
People with respiratory problems suffer from too much mucus production. Scientists are now analyzing the role of a protein that causes mucus build-up.
Advertisement
The team used mouse models of asthma and human airway tissue from asthmatic and non-asthmatic people to reach their findings.
Crucially, the paper highlighted the effectiveness of a class of drugs known as calcilytics in manipulating CaSR to reverse all symptoms associated with the condition. These symptoms include airway narrowing, airway twitchiness and inflammation, all of which contribute to increased breathing difficulty.
![Chewable Tablets For Asthma and Allergies Get FDA Approval]( "Chewable Tablets For Asthma and Allergies Get FDA Approval")
Montelukast Sodium chewable tablets formulated by Jubilant Life Sciences relieve symptoms of seasonal allergies and treats asthma.
Professor Daniela Riccardi, from Cardiff University School of Biosciences, said that their paper showed how these triggers release chemicals that activate CaSR in airway tissue and drive asthma symptoms like airway twitchiness, inflammation, and narrowing. Using calcilytics, nebulized directly into the lungs, they showed that it was possible to deactivate CaSR and prevent all of these symptoms, Riccardi further added.
According to Cardiff University Professor Paul Kemp, who co-authored the study, the identification of CaSR in airway tissue means that the potential for treatment of other inflammatory lung diseases beyond asthma was immense.
These include chronic obstructive pulmonary disease (COPD) and chronic bronchitis, for which currently there exists no cure. It is predicted that by 2020 these diseases will be the third biggest killers worldwide.
The study is published in Science Translational Medicine journal.
Source: ANI
Chewable Tablets For Asthma and Allergies Get FDA Approval
Montelukast Sodium chewable tablets formulated by Jubilant Life Sciences relieve symptoms of seasonal allergies and treats asthma.
Advertisement
Professor Daniela Riccardi, from Cardiff University School of Biosciences, said that their paper showed how these triggers release chemicals that activate CaSR in airway tissue and drive asthma symptoms like airway twitchiness, inflammation, and narrowing. Using calcilytics, nebulized directly into the lungs, they showed that it was possible to deactivate CaSR and prevent all of these symptoms, Riccardi further added.
According to Cardiff University Professor Paul Kemp, who co-authored the study, the identification of CaSR in airway tissue means that the potential for treatment of other inflammatory lung diseases beyond asthma was immense.
These include chronic obstructive pulmonary disease (COPD) and chronic bronchitis, for which currently there exists no cure. It is predicted that by 2020 these diseases will be the third biggest killers worldwide.
The study is published in Science Translational Medicine journal.
Source: ANI
Specific Protein Linked to Development of Asthma Paves Way for New Therapy
Scientists have linked a specific protein to the development of post-viral infection asthma, which is the first step in generating a novel type of asthma therapy designed to prevent its development in young children.
Advertisement
 Preventing Development of Asthma With Psychedelic DrugA psychedelic drug, (R)-DOI, may help prevent asthma development. Research led by Charles Nicholas has found that this drug prevents the development of allergic asthma in a mouse model. | Advertisement
|
Advertisement
Recommended Reading
Latest Drug News
India's First Urinary Incontinence Drug Fesobig may offer Affordable treatment for Overactive Bladder (OAB), a widely prevalent problem among Indian men and women.
Oral anticoagulant drugs, particularly Rivaroxaban presented superior efficacy and safety than warfarin in atrial fibrillation patients with chronic kidney disease.
Patients with hepatitis D virus-related chronic advanced liver disease are treated with an antiviral therapy.
Among people with COVID-19, Paxlovid drug was found to reduce hospitalization and death risk by 90%, revealed study.
Lilly will likely maintain or increase its market share in the insulin space as the average out-of-pocket cost for its insulin products is already below the $35 price cap.